Tislelizumab in Addition to BACE in Patients with NSCLC

Prior treatment

• Prior therapies of docetaxel or treatment targeting PD-1, PD-L1 or CTLA-4.
• Prior therapies of interventional therapy (I seeds implantation, Ablation, BACE).
• Prior allogeneic stem cell transplantation or organ transplantation
• With conditions requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone or equivalent) or other immunosuppressive medications

Other illness

• History of interstitial lung disease, non-infectious pneumonitis or participants with significantly impaired pulmonary function, or who require supplemental oxygen at baseline.
• Known HIV infection, participants with untreated chronic hepatitis B, active vaccination treatment.
• Active autoimmune diseases or history of autoimmune diseases that may relapse.

Lab values

• Harboring EGFR sensitizing mutation or ALK gene translocation

Other

• With uncontrollable pleural effusion, pericardial effusion, or clinically significant ascites requiring interventional treatment.
• Symptomatic central nervous system metastasis
• Known to be hypersensitive to contrast agent;
• Pregnant or breastfeeding women;
• Other protocol defined Inclusion/Exclusion criteria may apply

• Patient age between 18 and 75
• Signed Informed Consent Form.
• Confirmed TNM stage is III-Ⅳ of NSCLC ，and failed, refused or assessed ineligible to receive conventional treatments (surgery, chemoradiotherapy, Chemotherapy)；
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
• Adequate hematologic and end-organ function.
• Expected life span \> 3 months.
• Be able to provide fresh or archival tumor tissues for PD-L1 expression in tumor cells